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The DNA bank of Histocompatibility Laboratory “Jean Dausset”
in Saint Louis Hospital is one of the oldest and important of
HLA Labs in France. The first DNA samples were stored in
1989 and the total DNA samples today are >111000. Most of
the samples were extracted manually and from 2011 by automatic
methods (Fujifilm, Qiagen). For historical and practical reasons
all samples are stored at 4∘C. Eight or sixteen DNA samples,
depending on the year of extraction, were chosen at random - a
total of 136 samples. We tested the integrity and the quality of
DNA samples by a combination of several criteria: Monitoring of
DNA degradation by electrophoresis on agarose gel, DNA quality
control – by spectrophotometric analysis and pH control of storage
buffer Tris–EDTA (TE). We found deterioration in 22.8% of DNA
samples studied with a very significant degradation in 1992, 2009
and 2010. No degradation was observed for years 2000, 2002,
2004, 2006, 2012. Excluding the above mentioned years the results
show 9%DNA degradation between 1989 and 2012 and only 6% in
1989. We found contamination with RNA and protein respectively
in 18% and 3% and the pH< 7 in TE buffer in 76% of the studied
samples. No obvious correlation was found between DNA purity,
the pH and the DNA degradation. Our results suggest that genomic
DNA samples can be stored for a long time at 4 degrees C with
good yields and quality. The impact of manual extraction and
“homemade” buffers may reveal unpleasant surprises. That is why
the standardization of DNA extraction with the automats and the
use of commercial kits become essential. The storage of DNA
samples at 4 ∘C is an acceptable and cost-effective alternative
to expensive frozen storage and reduces the costs of biomedical
community.
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Since Korean society is fast becoming multi-ethnic, the determi-
nation of ambiguous HLA types using HLA allele frequencies is
losing its usefulness. We thus tried to develop new methods that
would directly resolve the ambiguities in HLA-DR genotyping
using blood from 150 unrelated healthy Koreans. All alleles of
HLA-DR were first amplified by 3 multi-group specific amplifi-
cation (MGSA) tubes and then sequenced. Tube 1 was designed
for DRB1*01, 15 and 16 allele groups, tube 2 for 03, 08, 10, 11,
12, 13 and 14, and tube 3 for 04, 07 and 09. Codon 86 GTG
PCR tube (tube 4) was added to solve phase ambiguity. Exon 2 of
the HLA-DRB1 locus was primarily analyzed. In cases of incom-
plete sequence ambiguity, additional exon 1, exon 3 and exon 3-4
were amplified. In case of phase ambiguity, Heterozygous Ambi-
guity Resolving Primer (HARP) was utilized. One case needed
re-sequencing after re-amplification using Group Specific Ampli-
fication (GSA) and Sequence Specific Primer (SSP). Our MGSA
method reduced the ambiguity to 9.3% while 42.7% of ambiguity
occurs in conventional SBT method. All of the phase ambiguities
were resolved by HARP, GSA, SSP or additional exon analyses.
In this study, 29 alleles and 14 serologic phenotypes were iden-
tified. None of same 4 digit allele had different 6 digit allele in
the test samples. However, 21.4% of alleles previously reported as
DRB1*12:01was identified asDRB1*12:10. In addition, all of pre-
viously reported DRB1*14:01 was identified as DRB1*14:54:01.
By using the algorithm proposed in this study, we could completely
solve the typing ambiguities of 150 Koreans. The algorithm which
uses MGSA tube from the beginning is somewhat expensive, but is
useful regarding timely and accurate reporting. TheMGSAmethod
is applicable to various populations and thus could be shared by
most HLA laboratories. However, since HARP and SSP should be
specific for a population, efforts to solve HLA ambiguity should
continue as a society is becoming multi-ethnic.
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Sarcoidosis is a multisystemic disorder of unknown etiology, char-
acterized by the formation of noncaseating granulomas, predomi-
nantly in the lungs and lymph nodes. The sarcoidosis association
with the ANXA11 rs1049550 SNP has been previously reported in
case–control studies. We carried out this meta-analysis in order
to collect all the relevant studies to further clarify the associ-
ation of ANXA11 SNP rs1049550 C/T (R230C variant) poly-
morphism with Sarcoidosis susceptibility. Relevant published data
were retrieved through Medline, PubMed and Web of Science per-
taining to Sarcoidosis and ANXA polymorphisms. Odds ratios
(OR) with 95 % confidence intervals (CI) were used to assess
the strength of the association. Z test was used to determine the
significance of the pooled OR. Statistical heterogeneity was mea-
sured using the Q statistic. The effect of heterogeneity was quan-
tified using the I2-statistic. Visual inspection of asymmetry in
funnel plots was conducted. Begg’s rank correlation method and
Egger weighted regression method were also used to statistically
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assess the publication bias. Statistical analyses were performed
with STATA12.0 software. A total of 6 studies, including 3297 sar-
coidosis cases and 3346 healthy controls, were collected in this
meta-analysis. For T vs. C, no heterogeneity (Q= 4.79, p= 0.44,
I2= 0.0%) was observed among individual estimates, and origi-
nal data were combined using the fixed-effects model. For the total
population, we found that ANXA11 T allele was less common in
the Sarcoidosis group than in the control group and we obtained
an effect summary OR= 0.69, with a 95 % CI= 0.64-0.74, and
p< 0.001, which shows a protective association of SNP rs1049550
T allele to sarcoidosis. Our comprehensive meta-analysis indi-
cated that there is sufficient evidence to demonstrate a conclusive
association between the ANXA11 SNP rs1049550 and sarcoidosis
susceptibility.
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In this paper we describe a subgroup-specific amplification assay
for HLA–DQA1 that encompasses the whole coding region
and allows us to sequence full length HLA-DQA1 genes. We
would like to introduce the novel alleles HLA-DQA1*01:10
and HLA-DQA1*01:11. Moreover, we were able to con-
firm the full length genomic sequence data of the alleles
HLA-DQA1*01:07, HLA-DQA1*03:01:01, HLA-DQA1*03:02,
HLA-DQA1*04:01:02, HLA-DQA1*04:02, HLA-DQA1*05:03,
HLA-DQA1*05:05:01:02 and HLA-DQA1*06:01:01. A complete
genomic overview of all six HLA-DQA1 allele groups is now avail-
able from the submission of our data to the IMGT/HLA database.
Since our approach facilitates the analysis of all HLA-DQA1 allele
sequences, HLA-DQA1 may become the first HLA locus from
which all subgroup members will be known in detail in the near
future.
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Routine human leukocyte antigen (HLA) typing for class I
(A*,B*,C*) and class II (DRB1*, DQB1*) by sequence based
typing of a male patient suffering from myelodysplastic syn-
drome was performed using commercial kits (Atria Genetics
Inc., South San Francisco, CA) following the manufacturer‘s
protocol. Allele assignment of HLA A exon 2, 3 and 4 with
SBTengine (Genome Diagnostics B.V, Utrecht, Netherlands) gave
no matched result with the currently used IMGT/HLA Database
suggesting the presence of a novel allele whereas additional SSP
typing (Olerup SSP AB, Stockholm, Sweden) showed no unclear
result. To separate both alleles, amplification and subsequent
sequence based typing with primers located in Intron 1 (5′-
GTCGGGCGGGTCTCAGCC - 3′) and allele-specific primers
located in intron 4 (5′- CAGAGAGGCTCCTGCTTTCCG - 3′ and
5′-CAGAGAGGCTCCTGCTTTCCC - 3′) was done. Sequence
analyses of the segregated alleles identified the common A*02:01
allele and the new A*32 allele identical to A*32:01 except one
nucleotide exchange in exon 4 at position 649 (G>A) causing an
amino acid exchange (Ala > Thr). The sequence was submitted to
EMBL Nucleotide Sequence Database and IMGT/HLA Sequence
Database under the accession number HE971711 and was offi-
cially named A*32:53 by the World Health Organization (WHO)
Nomenclature Committee.
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The HLA typing plays a crucial role in the selection of the unre-
lated donors for the hematopoietic stem cell transplantation. The
accuracy of the HLA registry typings of the donors is important
for timely search of the HLA matched donor for a specific patient.
The goal of this study is to analyse HLA discrepancies detected in
the verification typings performed during the search of the unre-
lated Czech donors in 2013. The primary registry HLA data were
originated in our laboratory as well as in our 7 cooperating donor
centres. The most volunteer donors were serologically typed for
HLA-A and HLA-B and DNA typed for DRB1 at the time of
recruitment. Newly all recruited donors have been DNA typed also
for HLA-A and HLA-B since 2009. HLA verification typings were
performed by DNA methods at a level of 2 or 4 digits. Verification
typing results were collected separately for HLA-A/B (serology),
HLA-A/B (DNA typing) and DRB1 (DNA typing). We analysed
498 verification typings in total (144 for HLA-A/B serology, 73
for HLA-A/B DNA typing and 281 for DRB1 DNA typing). We
detected 8 errors (5.6%) in the primary serological HLA data (4
errors at the locus A and 4 errors at the locus B). Discrepancies
were: homozygous serological typing vs. heterozygous DNA typ-
ing (i.e. serologically missed antigen, 4 errors), serological anti-
gen mistyping (3 errors) and serologically over-assigned antigen
(1 error). We detected 2 errors (0.7%) in DRB1 DNA registry typ-
ings. The second antigen was not identified in these both DRB1
DNA typings (i.e. false homozygosity). The allelic drop-out in SSO
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